Clinical and experimental advances in treatment of visceral leishmaniasis.
作者信息
Murray H W
机构信息
Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA.
出版信息
Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001.
Abstract
摘要
相似文献
1
Clinical and experimental advances in treatment of visceral leishmaniasis.内脏利什曼病治疗的临床与实验进展
Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001.
2
Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens.内脏利什曼病：诊断和治疗方案的最新进展。
Infect Dis Clin North Am. 2019 Mar;33(1):79-99. doi: 10.1016/j.idc.2018.10.005.
3
Visceral leishmaniasis therapy.内脏利什曼病的治疗
J Chemother. 1989 Jul;1(4 Suppl):956-9.
4
Miltefosine for visceral leishmaniasis.米替福新治疗内脏利什曼病。
N Engl J Med. 2000 Mar 23;342(12):894-5. doi: 10.1056/NEJM200003233421214.
5
Treatment of visceral leishmaniasis: options and choice.内脏利什曼病的治疗：选择与方案
Lancet Infect Dis. 2016 Feb;16(2):142-3. doi: 10.1016/S1473-3099(15)00528-9. Epub 2016 Jan 26.
6
Visceral leishmaniasis: can we dream its eradication?
J Assoc Physicians India. 2001 Jun;49:605-8.
7
Chemotherapy of cutaneous and visceral leishmaniasis in laboratory animals.
Dermatol Int. 1967 Jul-Sep;6(3):163-4. doi: 10.1111/j.1365-4362.1967.tb05257.x.
8
Current issues in the treatment of visceral leishmaniasis.内脏利什曼病治疗中的当前问题
Med Microbiol Immunol. 2001 Nov;190(1-2):81-4. doi: 10.1007/s004300100086.
9
[Visceral leishmaniasis: a new oral treatment?].[内脏利什曼病：一种新的口服治疗方法？]
Arch Pediatr. 1999 Jun;6(6):687-8. doi: 10.1016/s0929-693x(99)80305-4.
10
Visceral leishmaniasis in India.印度的内脏利什曼病
Lancet. 2000 Dec 2;356(9245):1933. doi: 10.1016/S0140-6736(05)73486-3.
引用本文的文献
1
Protein dysregulation during infection in anti-TNF immunosuppressed mice revealed through quantitative proteomics analysis of extracellular vesicles.通过细胞外囊泡的定量蛋白质组学分析揭示抗TNF免疫抑制小鼠感染期间的蛋白质失调。
Front Immunol. 2025 Jul 30;16:1634080. doi: 10.3389/fimmu.2025.1634080. eCollection 2025.
2
Unveiling the Interplay Between Dendritic Cells and Natural Killer Cells as Key Players in Infection.揭示树突状细胞与自然杀伤细胞在感染中作为关键参与者的相互作用。
J Immunol Res. 2025 Feb 10;2025:3176927. doi: 10.1155/jimr/3176927. eCollection 2025.
3
Pyrazolyl amide-chalcones conjugates: Synthesis and antikinetoplastid activity.吡唑基酰胺-查耳酮缀合物：合成与抗动质体活性
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4199-4210. doi: 10.1007/s00210-024-03524-7. Epub 2024 Oct 21.
4
The Elimination Status of Visceral Leishmaniasis in Southeast Asia Region.东南亚地区内脏利什曼病的消除状况。
Acta Parasitol. 2024 Sep;69(3):1704-1716. doi: 10.1007/s11686-024-00880-5. Epub 2024 Aug 20.
5
Immunosuppressants alter the immune response associated with Glucantime treatment for infection in a mouse model.免疫抑制剂改变了与 Glucantime 治疗感染相关的免疫反应在小鼠模型中。
Front Immunol. 2023 Dec 1;14:1285943. doi: 10.3389/fimmu.2023.1285943. eCollection 2023.
6
Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps.用于利什曼病的现场可部署治疗方法：内在挑战、最新进展及下一步措施
Res Rep Trop Med. 2023 Jul 20;14:61-85. doi: 10.2147/RRTM.S392606. eCollection 2023.
7
Old World Cutaneous Leishmaniasis: Successful response to topical imiquimod.旧世界皮肤利什曼病：对局部使用咪喹莫特治疗反应良好。
Sultan Qaboos Univ Med J. 2022 Aug;22(3):426-427. doi: 10.18295/squmj.9.2021.133. Epub 2022 Aug 25.
8
Activation of TLR-pathway to induce host Th1 immune response against visceral leishmaniasis: Involvement of galactosylated-flavonoids.激活TLR通路以诱导宿主针对内脏利什曼病的Th1免疫反应：半乳糖基化黄酮类化合物的作用。
Heliyon. 2022 Jul 3;8(7):e09868. doi: 10.1016/j.heliyon.2022.e09868. eCollection 2022 Jul.
9
Discovery and Validation of Lmj_04_BRCT Domain, a Novel Therapeutic Target: Identification of Candidate Drugs for Leishmaniasis.新型治疗靶点Lmj_04_BRCT结构域的发现与验证：利什曼病候选药物的鉴定
Int J Mol Sci. 2021 Sep 28;22(19):10493. doi: 10.3390/ijms221910493.
10
Synthesis of Tellurium Oxide (TeO) Nanorods and Nanoflakes and Evaluation of Its Efficacy Against Leishmania major In Vitro and In Vivo.氧化碲（TeO）纳米棒和纳米片的合成及其抗体内外利什曼原虫的效果评价。
Acta Parasitol. 2022 Mar;67(1):143-152. doi: 10.1007/s11686-021-00445-w. Epub 2021 Jun 26.
本文引用的文献
1
Practical progress and new drugs for changing patterns of leishmaniasis.改变利什曼病模式的实际进展与新药
Parasitol Today. 1993 Sep;9(9):323-8. doi: 10.1016/0169-4758(93)90231-4.
2
Modulating ongoing Th2-cell responses in experimental leishmaniasis.调节实验性利什曼病中正在进行的Th2细胞反应。
Parasitol Today. 1997 Feb;13(2):76-9. doi: 10.1016/s0169-4758(96)10078-8.
3
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.低剂量脂质体两性霉素B治疗难治性印度内脏利什曼病：一项多中心研究。
Am J Trop Med Hyg. 2002 Feb;66(2):143-6. doi: 10.4269/ajtmh.2002.66.143.
4
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.低剂量脂质体两性霉素B单次或每日输注治疗印度内脏利什曼病：随机试验
BMJ. 2001 Aug 25;323(7310):419-22. doi: 10.1136/bmj.323.7310.419.
5
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines.伊朗内脏利什曼病患者体内的白细胞介素-13：与其他Th2和Th1细胞因子的关系
Trans R Soc Trop Med Hyg. 2001 Jan-Feb;95(1):85-8. doi: 10.1016/s0035-9203(01)90344-x.
6
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.内脏利什曼病（黑热病）的治疗：十年进展与未来方法
Int J Infect Dis. 2000;4(3):158-77. doi: 10.1016/s1201-9712(00)90078-x.
7
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.注射用巴龙霉素（氨基糖苷）治疗内脏利什曼病：一项开放标签随机II期临床研究。
Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):432-3. doi: 10.1016/s0035-9203(00)90131-7.
8
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.一项关于巴龙霉素（氨基糖苷）加葡萄糖酸锑钠与单用葡萄糖酸锑钠治疗内脏利什曼病的安全性和有效性的前瞻性随机、对照、开放标签试验。
Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):429-31. doi: 10.1016/s0035-9203(00)90130-5.
9
Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil.
Braz J Infect Dis. 1997 Oct;1(5):230-240.
10
Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.内源性白细胞介素-4是有效治疗内脏利什曼病药物疗法所必需的。
Eur J Immunol. 2000 Oct;30(10):2935-43. doi: 10.1002/1521-4141(200010)30:10<2935::AID-IMMU2935>3.0.CO;2-Q.
Zotero 插件